Biota Holdings Limited (ASX:BTA)(PNK:BTAHY) today announced that it had received written notification from GlaxoSmithKline (GSK) that Relenza sales were $27.1 million and indicative royalties were $1.9 million, for the three months ended 30 September 2008.
Leading developer of RNA interference (RNAi)-based therapeutics Benitec Limited (ASX:BLT)(PINK:BNIKF) announced today that Dr John Zaia, had presented an update on the human HIV trial at the 2nd Annual Cambridge Healthtech Institute's "RNAi for Therapeutics" conference held in Boston, MA USA 22-23rd October 2008.
The Directors of Benitec Limited (ASX:BLT)(PINK:BNIKF) are pleased to announce a placement of 43,793,232 shares and one for one free attaching options to raise AUD$1.97 million.
Benitec Limited (ASX:BLT)(PINK:BNIKF) today announced that a key patent "Control of Gene Expression" part of the Graham patent family of RNA interference (RNAi) patents was granted in New Zealand. The "Control of Gene Expression patent" is a patent in the foundational Graham RNAi patent family and is related to the '099 patent currently under reexamination at the USPTO.
Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced successful early safety results in the world's first clinical trial to use allogeneic, or "off-the-shelf", adult stem cells from an unrelated donor to treat patients with congestive heart failure.
Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that its United States-based sister company, Angioblast Systems Inc., was featured at the 2008 UBS Global Life Sciences Conference underway in New York.
Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that its commercial and business activities are being highlighted at The World Stem Cell Summit in Wisconsin, United States, on 23 September 2008.
